The fact that the reason for the different clinical course and biology of the ILC subtype of BC has begun to be revealed raises our hopes that the treatment options will also differ in the coming years and that the risk of developing late recurrence and metastasis will be reduced or eliminated with more effective treatments. This evidence concerns the gene CCL27 and breast cancer.